Your browser doesn't support javascript.
loading
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET).
Jerusalem, G; Mariani, G; Ciruelos, E M; Martin, M; Tjan-Heijnen, V C G; Neven, P; Gavila, J G; Michelotti, A; Montemurro, F; Generali, D; Simoncini, E; Lang, I; Mardiak, J; Naume, B; Camozzi, M; Lorizzo, K; Bianchetti, S; Conte, P.
Afiliação
  • Jerusalem G; Department of Medical Oncology, CHU Sart Tilman Liege and Liege University, Domaine Universitaire du Sart Tilman, Liege, Belgium g.jerusalem@chu.ulg.ac.be.
  • Mariani G; Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
  • Ciruelos EM; Medical Oncology Department, Breast Cancer Unit, University Hospital 12 de Octubre, Madrid, Spain.
  • Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, Univesidad Complutense, Madrid, Spain.
  • Tjan-Heijnen VC; Department of Medical Oncology, GROW, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Neven P; KULeuven (University of Leuven), Department of Oncology, Multidisciplinary Breast Center, University Hospitals Leuven, Belgium.
  • Gavila JG; Medical Oncology Unit of Fundacion Instituto Valenciano De Oncologia, Valencia, Spain.
  • Michelotti A; UO Oncologia Medica I, Azienda Ospedaliera Universitaria Pisana, Santa Chiara Hospital, Pisa, Italy.
  • Montemurro F; Unit of Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia, Institute of Candiolo Cancer Center (IRCCs), Candiolo, Torino, Italy.
  • Generali D; Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
  • Simoncini E; Breast Unit, Azienda Ospedaliera Spedali Civili, Brescia, Italy.
  • Lang I; Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary.
  • Mardiak J; Narodny Onkologicky Ustav Klenova 1, Bratislava, Slovakia.
  • Naume B; Department of Oncology, Oslo University Hospital, Oslo, Norway K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Camozzi M; Novartis Farma S.p.A., Origgio, VA, Italy.
  • Lorizzo K; Novartis Farma S.p.A., Origgio, VA, Italy.
  • Bianchetti S; Novartis Farma S.p.A., Origgio, VA, Italy.
  • Conte P; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy Medical Oncology 2, Istituto Oncologico Veneto, Padova, Italy.
Ann Oncol ; 27(9): 1719-25, 2016 09.
Article em En | MEDLINE | ID: mdl-27358383
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Everolimo / Androstadienos / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Bélgica
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Everolimo / Androstadienos / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Bélgica